Verastem Inc., of Boston, reduced its work force by approximately half, to 20 full-time employees, following its decision last month to halt the pivotal phase II COMMAND study after lead candidate VS-6063 (defactinib) failed to show efficacy in treating malignant pleural mesothelioma.